Edmond DE Rothschild Holding S.A. purchased a new stake in DexCom, Inc. (NASDAQ:DXCM – Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 74,350 shares of the medical device company’s stock, valued at approximately $5,007,000.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in DXCM. Reflection Asset Management acquired a new position in shares of DexCom in the 4th quarter valued at $25,000. Ascentis Independent Advisors acquired a new stake in shares of DexCom during the 1st quarter worth about $25,000. MCF Advisors LLC acquired a new stake in shares of DexCom during the 4th quarter worth about $32,000. Wellington Grp LLC increased its position in shares of DexCom by 778.7% during the 1st quarter. Wellington Grp LLC now owns 536 shares of the medical device company’s stock worth $34,000 after purchasing an additional 475 shares during the last quarter. Finally, DV Equities LLC purchased a new stake in shares of DexCom in the 4th quarter valued at approximately $36,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.
DexCom Stock Up 0.3%
Shares of NASDAQ:DXCM opened at $89.88 on Thursday. The company has a market capitalization of $33.92 billion, a PE ratio of 35.53, a P/E/G ratio of 1.51 and a beta of 1.41. The company has a current ratio of 1.73, a quick ratio of 1.43 and a debt-to-equity ratio of 0.47. DexCom, Inc. has a twelve month low of $54.11 and a twelve month high of $91.96. The firm has a 50 day simple moving average of $76.85 and a 200-day simple moving average of $70.67.
Insider Activity at DexCom
In other DexCom news, EVP Jon Coleman sold 4,912 shares of the firm’s stock in a transaction dated Wednesday, June 3rd. The stock was sold at an average price of $73.00, for a total transaction of $358,576.00. Following the transaction, the executive vice president owned 100,361 shares of the company’s stock, valued at approximately $7,326,353. This trade represents a 4.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,756 shares of DexCom stock in a transaction dated Monday, July 20th. The stock was sold at an average price of $76.32, for a total value of $2,042,017.92. Following the sale, the insider owned 328,970 shares in the company, valued at $25,106,990.40. This trade represents a 7.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 73,035 shares of company stock worth $5,446,673. Insiders own 0.28% of the company’s stock.
Analysts Set New Price Targets
Several equities research analysts recently issued reports on DXCM shares. Argus boosted their price objective on DexCom from $86.00 to $96.00 and gave the company a “buy” rating in a report on Tuesday, August 4th. Truist Financial set a $93.00 price objective on shares of DexCom and gave the stock a “buy” rating in a research report on Friday, July 31st. Raymond James Financial reiterated a “strong-buy” rating and set a $94.00 target price on shares of DexCom in a research note on Friday, July 31st. Wall Street Zen lowered DexCom from a “strong-buy” rating to a “buy” rating in a report on Sunday, May 10th. Finally, Stifel Nicolaus set a $95.00 price target on DexCom and gave the company a “buy” rating in a research note on Friday, July 31st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $88.71.
Read Our Latest Stock Report on DXCM
About DexCom
DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.
Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.
Further Reading
- Five stocks we like better than DexCom
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM – Free Report).
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.
